Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events
About this episode
This episode discusses the emergency care of cancer patients receiving CAR T-cell and bispecific antibody immunotherapies and the associated adverse events.
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present to the emergency room with symptoms of adverse effects (AEs). While T-cell-retargeting therapies have revolutionized the treatment of hematological malignancies, they are also associated with symptoms of cytokine release syndrome (CRS), immune effector c...
More episodes of CEConversations
- A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
- Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
- Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN
- Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
- MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management
- Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies
Explore listener stats, chart rankings, contacts and more on the CEConversations podcast page.